vor 2 Jahren

Life Sciences Report 2017 / 2018

  • Text
  • Technology
  • Medicine
  • Pharma
  • Berlin
  • Innovative
  • Clinical
  • Sciences
  • Solutions
  • Pharmaceutical
  • Biotech
  • Diagnostics

8 Life

8 Life Sciences Report – Companies and Jobs – Facts and Figures research, and are also part of the process in manufacturing pharmaceutical preparations. Eternygen GmbH, a company focused on metabolic disorders, successfully obtained series A financing of € 8.0 million. Eternygen’s research and development is focused on sodium-dependent citrate transporters, a new target also known under the name INDY (I am Not Dead Yet). INDY is a central regulator of energy transition and metabolism, and is involved in the pathogenesis of non-alcoholic fatty liver, non-alcoholic steatohepatitis, diabetes, and obesity. Glycotope GmbH, a global leader in glyco-optimization of biopharmaceuticals, and Octapharma AG, one of the world’s largest human protein product manufacturers, entered into an exclusive worldwide licensing agreement for Glycotope’s preclinical human blood coagulation factors based on its GlycoExpress(TM) technology platform. In addition, Octapharma captured a stake in the company by purchasing new Glycotope shares generated through a capital increase. Glycotope received an initial payment of € 80 million from Octapharma. Production of test kits for ifp Institut für Produktqualität GmbH moved to the new company headquarters in Berlin-Adlershof at the end of September 2016. The production department, which manufactures test kits developed by ifp (rapid tests for allergens, ELISAs, vitamin assays, enzymatic kits and real-time PCR kits) was the last division remaining at the old location in Berlin-Steglitz. After the main building was completed at the end of 2015, both a production building and a warehouse and administrative building were finished in 2016. ifp has invested a total of over € 30 million for the five new buildings in Adlershof since 2013. USA company Bruker acquired InVivo Biotech Services GmbH. In addition to its core business, which focuses on producing monoclonal antibodies and recombinant proteins, InVivo has experience in producing consumable materials and diagnostic reagents, so-called kits. Bruker is an international group which facilitates better marketing for the company’s core business, especially in the USA and Asia. The company will retain its name, management, and locations in Hennigsdorf and Berlin. InVivo will be hiring additional employees as early as 2017 in relation to its new projects with Bruker. MagForce AG, a leading medical technology company focused on nanotechnology and on the oncology area, successfully completed a capital increase campaign in 2017. The gross issue proceeds were € 5.0 million, which are primarily being used to accelerate the international explosion of MagForce. Cardiovascular Technologies 12% 36 Minimally Invasive Medicine 12% 38 Medtech Arthroplasty 15% 45 Biotech Diagnostic Imaging 16% 49 e-Health 32% 97 Service Provider 17% 52 New Therapeutics and Diagnostics 57% 130 Industrial Biotechnology 20% 45 Agriculture/Food 12% 27 Biomedicine Service Provider 44% 101 10 20 30 40 50 60 70 80 90 100 110 120 130 No. of Companies Market Segments of Companies Source: Internal Survey HealthCapital, May 2017, multiple entries

Life Sciences Report – Companies and Jobs – Facts and Figures 9 © Takeda Deutschland / Marco Urban © ifp Institut für Produktqualität GmbH Dr. Wolfgang Weber General Manager ifp Institut für Produktqualität GmbH OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics to prevent and treat cardiovascular diseases, announced the closing of a Series B financing round worth € 8.3 million and the initiation of a Phase 1 clinical trial with lead compound OMT-28 for treating atrial fibrillation. The funding will be used to support the newly initiated clinical program and to further leverage the therapeutic potential of the technology. Organobalance GmbH, which specializes in microbial screening processes and bioassay development, will supplement Novozymes’ existing platform with applications for a wide variety of industrial sectors. Novozymes announced it would be acquiring Organobalance GmbH in 2016. The company, which has locations in Berlin and Flensburg, is still headquartered in Germany. It will be able to benefit from established biotechnology capabilities in the capital city region from there. Pfizer is combining its trusted medicines and medications from the company Hospira, which it took over in 2016, under a new subsidiary: Pfizer Pharma PFE GmbH. The portfolio of the newly founded company encompasses over 100 medications, and it will be managed under the aegis of Pfizer Deutschland GmbH in Berlin. “Our institute has found an ideal home on the Berlin Adlershof science campus. Looking back on it, building at this location, which is imbued with innovation and a pioneering spirit, was the right decision. The outstanding corporate development and the support we received from location management allowed us to significantly expand the facilities later on and increase our staff to over 300 employees. That means we’re ideally set up for the future.” S·CAPE® recently completed an investment of over € 20 million in its headquarters in Berlin-Tempelhof. Further investments in research and development will be made at the location through 2019, and the workforce will be increased to 150 employees. Takeda has been investing € 100 million into new facilities at Oranienburg to expand its production capacity. The inauguration of the new production unit was accompanied by Chancellor Angela Merkel in June 2017 and through this expansion 180 new jobs and training places have been created. The first units are already in operation. Ottobock intends to expand its activities on the former Bötzow Brewery grounds, focusing on innovation and start-ups, by expanding and renovating the protected historical building. In addition, other Ottobock areas will be moving from the Ottobock Science Center Berlin and the Näder Family Office to the newly renovated building section. In the future, up to 200 Ottobock employees will be working on Bötzow grounds. Many different companies in the region are continuously expanding their international activities. For instance, SCIENION AG established a new branch in France, BIOTRONIK founded a new production location in Singapore, and EPO Berlin-Buch GmbH established a strategic partnership for the USA market. “In everything we do, we put the patient first. As a research-driven specialty care provider we focus on oncology and gastroenterology and dedicate our work to improving quality of life for patients by translating science into life-changing medicines – globally and locally. Takeda has been investing 100 million Euro in the expansion of our Oranienburg site, creating new jobs and offering opportunities for young people. With more than 1,000 employees at our headquarters in Berlin and our plant in Oranienburg we have a strong footprint in the Berlin-Brandenburg region and are a proud and reliable partner for our stakeholders in the healthcare system.” Günter Kloucek General Manager, Takeda Germany

Publications in English

Publikationen auf deutsch

Clusterreport Verkehr, Mobilität und Logistik
Automotive in der Hauptstadtregion Berlin-Brandenburg
Aerospace Industrie
Biotech- und Pharmaindustrie
Forschung für die Gesundheit
Gesundheitsversorgung und Prävention
Potenzialstudie Medizintourismus Berlin-Brandenburg_2015
Clusterbroschuere Gesundheitswirtschaft
Prävention und Gesundheitsförderung
Rehabilitation in Berlin und Brandenburg
Games Industrie in der Hauptstadtregion Berlin-Brandenburg
Digitale Wirtschaft in Berlin
Fernsehen in der Hauptstadtregion Berlin-Brandenburg
Fashion in Berlin
Best Practice Wireless in der Hauptstadtregion Berlin-Brandenburg
Medien und Kreativwirtschaft in Berlin-Brandenburg
Turbomaschinen und Kraftwerkstechnik
Energienetze und -speicher in der Hauptstadtregion Berlin-Brandenburg
Kreislaufwirtschaft in Berlin
Wasserwirtschaft in Berlin
Energietechnik in der Hauptstadtregion Berlin-Brandenburg
Inkubationsprogramme in der Energiewirtschaft
Service Packages für Unternehmen in Berlin
Unternehmensservice in den Berliner Bezirken
Berlin Partner: Unser Service fuer Sie